DK2152712T3 - Aminoheterocykliske fobindelser - Google Patents

Aminoheterocykliske fobindelser

Info

Publication number: DK2152712T3
Authority: DK; Denmark
Prior art keywords: pho; connections; amino heterocyclic; heterocyclic; amino
Prior art date: 2007-05-11

Application number

DK08737600.0T

Other languages

English (en)

Inventor

Patrick Robert Verhoest

Caroline Proulx-Lafrance

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-11

Filing date

2008-05-05

Publication date

2012-03-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39672073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2152712(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-05 Application filed by Pfizer filed Critical Pfizer

2012-03-26 Application granted granted Critical

2012-03-26 Publication of DK2152712T3 publication Critical patent/DK2152712T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Virology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

DK08737600.0T 2007-05-11 2008-05-05 Aminoheterocykliske fobindelser DK2152712T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US6091707A	2007-05-11	2007-05-11
US91733307P	2007-05-11	2007-05-11
PCT/IB2008/001125 WO2008139293A1 (en)	2007-05-11	2008-05-05	Amino-heterocyclic compounds

Publications (1)

Publication Number	Publication Date
DK2152712T3 true DK2152712T3 (da)	2012-03-26

Family

ID=39672073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08737600.0T DK2152712T3 (da)	2007-05-11	2008-05-05	Aminoheterocykliske fobindelser

Country Status (43)

Country	Link
US (1)	US7964607B2 (da)
EP (1)	EP2152712B1 (da)
JP (1)	JP4579346B2 (da)
KR (1)	KR101222330B1 (da)
CN (1)	CN101687876B (da)
AP (1)	AP2524A (da)
AR (1)	AR066502A1 (da)
AT (1)	ATE540954T1 (da)
AU (1)	AU2008249750B2 (da)
BR (1)	BRPI0811280B8 (da)
CA (1)	CA2687035C (da)
CL (1)	CL2008001374A1 (da)
CO (1)	CO6241157A2 (da)
CR (1)	CR11095A (da)
CU (1)	CU23834B1 (da)
CY (1)	CY1112332T1 (da)
DK (1)	DK2152712T3 (da)
DO (1)	DOP2009000258A (da)
EA (1)	EA016510B1 (da)
EC (1)	ECSP099728A (da)
ES (1)	ES2377849T3 (da)
GE (1)	GEP20125405B (da)
GT (1)	GT200900294A (da)
HR (1)	HRP20120105T1 (da)
IL (1)	IL201977A (da)
MA (1)	MA31373B1 (da)
ME (1)	ME00954B (da)
MX (1)	MX2009011830A (da)
MY (1)	MY147330A (da)
NI (1)	NI200900204A (da)
NZ (1)	NZ580904A (da)
PA (1)	PA8779901A1 (da)
PE (1)	PE20090247A1 (da)
PL (1)	PL2152712T3 (da)
PT (1)	PT2152712E (da)
RS (1)	RS52166B (da)
SI (1)	SI2152712T1 (da)
SV (1)	SV2009003411A (da)
TN (1)	TN2009000471A1 (da)
TW (1)	TWI362262B (da)
UA (1)	UA94660C2 (da)
WO (1)	WO2008139293A1 (da)
ZA (1)	ZA200907776B (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
PE20091211A1 (es)	2007-11-30	2009-09-14	Boehringer Ingelheim Int	Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) *	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja)	2008-09-08	2014-03-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
MY159826A (en)	2008-11-19	2017-02-15	Forum Pharmaceuticals Inc	Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TWI404721B (zh)	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
EP2414363B1 (en)	2009-03-31	2014-01-08	Boehringer Ingelheim International GmbH	1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
PE20120324A1 (es) *	2009-05-11	2012-04-17	Envivo Pharmaceuticals Inc	Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
WO2010132127A1 (en)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Organic compounds
US8858911B2 (en) *	2009-10-08	2014-10-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
LT3029039T (lt)	2010-05-17	2018-02-26	Forum Pharmaceuticals Inc.	Farmacinės kompozicijos, apimančios (r)-7-chlor-n-(chinuklidin-3-il)benzo(b)tiofen-2-karboksamido hidrochlorido monohidrato kristalines formas
PE20130602A1 (es)	2010-08-12	2013-05-25	Boehringer Ingelheim Int	Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
MX2013002584A (es)	2010-09-07	2013-04-29	Astellas Pharma Inc	Compuesto de pirazoloquinolina.
BR112013008140A8 (pt)	2010-09-20	2018-04-03	Envivo Pharmaceuticals Inc	"compostos imidazotriazinona".
US20130040971A1 (en) *	2011-02-14	2013-02-14	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) *	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AU2012319549B2 (en)	2011-10-07	2016-07-28	Eisai R&D Management Co., Ltd.	Pyrazoloquinoline derivative
BR112015007731B1 (pt)	2011-10-10	2022-05-31	H. Lundbeck A/S	Composto, composição farmacêutica que o compreende e uso do mesmo
EP2807163B1 (en) *	2012-01-26	2017-03-22	H. Lundbeck A/S	Pde9 inhibitors with imidazo triazinone backbone
WO2013142269A1 (en) *	2012-03-19	2013-09-26	Envivo Pharmaceuticals, Inc.	Imidazotriazinone compounds
CA2872005A1 (en)	2012-05-08	2013-11-14	Forum Pharmaceuticals, Inc.	Methods of maintaining, treating or improving cognitive function
CN105732639A (zh)	2012-06-29	2016-07-06	辉瑞大药厂	作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
WO2014024125A1 (en)	2012-08-08	2014-02-13	Celon Pharma S.A.	Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
EP2956141A4 (en)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	NEW USES
MX359843B (es)	2013-04-05	2018-10-12	Eisai R&D Man Co Ltd	Sal de derivado de pirazoloquinolina y cristal de la misma.
CA2904820C (en)	2013-04-05	2021-05-18	Eisai R&D Management Co., Ltd.	Pyridinylpyrazoloquinoline compound
CN103626774B (zh) *	2013-11-20	2015-11-04	苏州明锐医药科技有限公司	伊鲁替尼的制备方法
WO2015092592A1 (en)	2013-12-17	2015-06-25	Pfizer Inc.	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
ES2745819T3 (es)	2014-08-07	2020-03-03	Intra Cellular Therapies Inc	Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
BR112017005533B1 (pt) *	2014-09-17	2023-10-10	Intra-Cellular Therapies, Inc	Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
TW201629064A (zh)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	作爲ｐｄｅ１抑制劑之三唑並吡酮
BR112017012005B1 (pt) *	2014-12-06	2023-04-04	Intra-Cellular Therapies, Inc	Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
BR112017012007B1 (pt)	2014-12-06	2022-11-01	Intra-Cellular Therapies, Inc	Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
EP3237401B1 (en)	2014-12-22	2019-03-06	Pfizer Inc	Antagonists of prostaglandin ep3 receptor
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
HUE065652T2 (hu) *	2015-07-07	2024-06-28	H Lundbeck As	Imidazo-pirazinon vázzal rendelkezõ PED9 inhibitor perifériális betegségek kezelésére
EP3350178B1 (en)	2015-09-14	2021-10-20	Pfizer Inc.	Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
JP6983161B2 (ja)	2015-09-15	2021-12-17	プラクシス・バイオリサーチ・エルエルシー	フェンカンファミンのプロドラッグ
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN108368121B (zh)	2015-10-16	2023-01-13	艾伯维公司	制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物的方法
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN105669680B (zh) *	2016-03-24	2018-02-23	南京药捷安康生物科技有限公司	吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2017172795A1 (en)	2016-03-28	2017-10-05	Intra-Cellular Therapies, Inc.	Novel compositions and methods
TWI729109B (zh) *	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN114903900A (zh)	2016-07-06	2022-08-16	伊马拉公司	用于治疗外周疾病的pde9抑制剂
CN109843884B (zh)	2016-10-18	2022-03-04	H.隆德贝克有限公司	作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
CN109803653A (zh)	2016-10-28	2019-05-24	H.隆德贝克有限公司	包括给予咪唑并吡嗪酮的组合治疗
WO2018078038A1 (en)	2016-10-28	2018-05-03	H. Lundbeck A/S	Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
JP7111720B2 (ja)	2016-12-28	2022-08-02	ダート・ニューロサイエンス・エルエルシー	Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
ES2969895T3 (es)	2017-05-26	2024-05-23	Cardurion Pharmaceuticals Inc	Métodos para obtener y usar inhibidores de PDE9
EP3632438B1 (en)	2017-06-01	2023-08-23	Eisai R&D Management Co., Ltd.	Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
JP7177772B2 (ja) *	2017-06-01	2022-11-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
US11484502B2 (en)	2017-06-01	2022-11-01	Eisai R&D Management Co., Ltd.	Pharmaceutical composition comprising PDE9 inhibitor
RU2019135834A (ru)	2017-06-01	2021-07-13	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
CA3064938A1 (en)	2017-06-08	2018-12-13	Merck Sharp & Dohme Corp.	Pyrazolopyrimidine pde9 inhibitors
ES2902365T3 (es)	2017-11-27	2022-03-28	Dart Neuroscience Llc	Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
CN110357888A (zh) *	2018-04-09	2019-10-22	南京药捷安康生物科技有限公司	杂环磷酸二酯酶抑制剂及其用途
FI3801526T3 (fi)	2018-05-25	2024-03-20	Cardurion Pharmaceuticals Inc	6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
KR102831968B1 (ko)	2018-08-31	2025-07-08	카듀리온 파마슈티칼스, 인크.	겸상 세포 질환의 치료를 위한 pde9 억제제
JP7480135B2 (ja) *	2018-10-21	2024-05-09	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
KR102706457B1 (ko) *	2018-12-06	2024-09-11	한국화학연구원	Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CN111471059B (zh)	2019-01-23	2022-12-02	药捷安康(南京)科技股份有限公司	Pde9抑制剂及其用途
WO2022182658A1 (en)	2021-02-23	2022-09-01	Hoth Therapeutics, Inc.	Use of aprepitant for treating alzheimer's disease
EP4448529A1 (en)	2021-12-16	2024-10-23	Pfizer Inc.	Solid forms of pyrazolo[3,4-d]pyrimidine compounds
IL314895A (en) *	2022-02-16	2024-10-01	Duke Street Bio Ltd	Pharmaceutical compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020156277A1 (en)	2001-04-20	2002-10-24	Fick David B.	Synthesis and methods of use of purine analogues and derivatives
US20040176361A1 (en)	2001-05-23	2004-09-09	Masakazu Fujio	Fused heterocyclic compound and medicinal use thereof
HUP0401998A2 (hu) *	2001-11-02	2005-01-28	Pfizer Products Inc.,	PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
HN2002000317A (es) *	2001-11-02	2003-05-21	Pfizer	Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
WO2004008230A2 (en) *	2002-07-12	2004-01-22	Massachusetts Institute Of Technology	Reconfigurable microphotonics devices via deformable membrane platform
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
DE10238722A1 (de) *	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US7051174B2 (en) *	2002-09-24	2006-05-23	International Business Machines Corporation	Method, system, and program for restoring data in cache
AU2003301662A1 (en)	2002-10-21	2004-05-13	Bristol-Myers Squibb Company	Quinazolinones and derivatives thereof as factor xa inhibitors
US7111287B2 (en) *	2003-01-10	2006-09-19	International Business Machines Corporation	Global processor resource assignment in an assembler
DE602004007840T2 (de)	2003-03-18	2008-04-10	The Jordanian Pharmaceutical Manufacturing Co. Ltd.	Pyrazolopyrimidinon und ihre Verwendung als PDE-Inhibitoren
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
DE10320785A1 (de) *	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine

2008
- 2008-05-05 ES ES08737600T patent/ES2377849T3/es active Active
- 2008-05-05 MX MX2009011830A patent/MX2009011830A/es active IP Right Grant
- 2008-05-05 BR BRPI0811280A patent/BRPI0811280B8/pt active IP Right Grant
- 2008-05-05 GE GEAP200811556A patent/GEP20125405B/en unknown
- 2008-05-05 NZ NZ580904A patent/NZ580904A/en unknown
- 2008-05-05 EA EA200901373A patent/EA016510B1/ru unknown
- 2008-05-05 JP JP2010507997A patent/JP4579346B2/ja active Active
- 2008-05-05 AT AT08737600T patent/ATE540954T1/de active
- 2008-05-05 CN CN2008800242732A patent/CN101687876B/zh active Active
- 2008-05-05 CA CA2687035A patent/CA2687035C/en active Active
- 2008-05-05 PL PL08737600T patent/PL2152712T3/pl unknown
- 2008-05-05 DK DK08737600.0T patent/DK2152712T3/da active
- 2008-05-05 ME MEP-2009-330A patent/ME00954B/me unknown
- 2008-05-05 UA UAA200911482A patent/UA94660C2/ru unknown
- 2008-05-05 EP EP08737600A patent/EP2152712B1/en active Active
- 2008-05-05 WO PCT/IB2008/001125 patent/WO2008139293A1/en active Application Filing
- 2008-05-05 PT PT08737600T patent/PT2152712E/pt unknown
- 2008-05-05 RS RS20120094A patent/RS52166B/en unknown
- 2008-05-05 AU AU2008249750A patent/AU2008249750B2/en active Active
- 2008-05-05 HR HR20120105T patent/HRP20120105T1/hr unknown
- 2008-05-05 SI SI200830543T patent/SI2152712T1/sl unknown
- 2008-05-05 MY MYPI20094735A patent/MY147330A/en unknown
- 2008-05-05 AP AP2009005048A patent/AP2524A/xx active
- 2008-05-05 KR KR1020097025802A patent/KR101222330B1/ko active Active
- 2008-05-08 PE PE2008000812A patent/PE20090247A1/es active IP Right Grant
- 2008-05-09 PA PA20088779901A patent/PA8779901A1/es unknown
- 2008-05-09 AR ARP080101964A patent/AR066502A1/es active IP Right Grant
- 2008-05-09 CL CL2008001374A patent/CL2008001374A1/es unknown
- 2008-05-09 US US12/118,062 patent/US7964607B2/en active Active
- 2008-05-09 TW TW097117227A patent/TWI362262B/zh active
2009
- 2009-11-05 ZA ZA2009/07776A patent/ZA200907776B/en unknown
- 2009-11-05 CR CR11095A patent/CR11095A/es unknown
- 2009-11-05 IL IL201977A patent/IL201977A/en not_active IP Right Cessation
- 2009-11-06 CU CU2009000184A patent/CU23834B1/es active IP Right Grant
- 2009-11-06 TN TNP2009000471A patent/TN2009000471A1/fr unknown
- 2009-11-09 NI NI200900204A patent/NI200900204A/es unknown
- 2009-11-10 CO CO09127785A patent/CO6241157A2/es active IP Right Grant
- 2009-11-10 GT GT200900294A patent/GT200900294A/es unknown
- 2009-11-10 DO DO2009000258A patent/DOP2009000258A/es unknown
- 2009-11-10 EC EC2009009728A patent/ECSP099728A/es unknown
- 2009-11-11 MA MA32341A patent/MA31373B1/fr unknown
- 2009-11-11 SV SV2009003411A patent/SV2009003411A/es unknown
2012
- 2012-02-06 CY CY20121100125T patent/CY1112332T1/el unknown

Also Published As

Publication number	Publication date
NZ580904A (en)	2012-02-24
EA016510B1 (ru)	2012-05-30
SI2152712T1 (sl)	2012-03-30
TN2009000471A1 (fr)	2011-03-31
ZA200907776B (en)	2011-01-26
NI200900204A (es)	2010-03-11
AU2008249750A1 (en)	2008-11-20
CR11095A (es)	2009-12-04
AP2009005048A0 (en)	2009-12-31
ES2377849T3 (es)	2012-04-02
SV2009003411A (es)	2010-05-21
AR066502A1 (es)	2009-08-26
CA2687035A1 (en)	2008-11-20
EP2152712A1 (en)	2010-02-17
WO2008139293A1 (en)	2008-11-20
CU23834B1 (es)	2012-10-15
BRPI0811280B8 (pt)	2021-05-25
CO6241157A2 (es)	2011-01-20
KR20100007985A (ko)	2010-01-22
CL2008001374A1 (es)	2008-11-14
TW200902015A (en)	2009-01-16
HRP20120105T1 (hr)	2012-02-29
BRPI0811280B1 (pt)	2021-05-11
IL201977A (en)	2014-07-31
CY1112332T1 (el)	2015-12-09
JP2010526863A (ja)	2010-08-05
CN101687876A (zh)	2010-03-31
IL201977A0 (en)	2010-06-16
ATE540954T1 (de)	2012-01-15
PL2152712T3 (pl)	2012-05-31
EP2152712B1 (en)	2012-01-11
MY147330A (en)	2012-11-30
JP4579346B2 (ja)	2010-11-10
AP2524A (en)	2012-12-04
GT200900294A (es)	2011-08-29
MA31373B1 (fr)	2010-05-03
US7964607B2 (en)	2011-06-21
DOP2009000258A (es)	2010-05-15
RS52166B (en)	2012-08-31
UA94660C2 (en)	2011-05-25
PA8779901A1 (es)	2008-12-18
ME00954B (me)	2012-06-20
PE20090247A1 (es)	2009-03-13
HK1142595A1 (en)	2010-12-10
CA2687035C (en)	2011-09-20
BRPI0811280A2 (pt)	2015-01-20
GEP20125405B (en)	2012-02-27
PT2152712E (pt)	2012-02-29
MX2009011830A (es)	2009-11-13
KR101222330B1 (ko)	2013-01-15
AU2008249750B2 (en)	2011-07-14
ECSP099728A (es)	2009-12-28
TWI362262B (en)	2012-04-21
CU20090184A7 (es)	2011-07-11
US20090030003A1 (en)	2009-01-29
EA200901373A1 (ru)	2010-06-30
CN101687876B (zh)	2012-12-12

Publication	Publication Date	Title
DK2152712T3 (da)	2012-03-26	Aminoheterocykliske fobindelser
LTC2170860I2 (lt)	2022-03-10	Benzimidazolo dariniai
DK3118221T3 (da)	2019-09-23	Proteiner
EP2139906A4 (en)	2011-08-03	aminophosphine
LU92600I2 (fr)	2015-11-24	Sovaldi (sofosbuvir)
DK2164844T3 (da)	2012-08-20	Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da)	2013-06-03	Pyrimidinsubstituerede purinderivater
BRPI0818457A2 (pt)	2015-04-14	Derivados de oxadiazol
BRPI0812350A2 (pt)	2015-02-10	Conexão
DE602008002205D1 (de)	2010-09-30	Neuartige verbindungen
BRPI0813836A2 (pt)	2015-01-06	Derivados pirazólicos
ATE515289T1 (de)	2011-07-15	Arylether-pyridazinonderivate
DK2227466T3 (da)	2011-08-08	Heteroaryl-substituerede piperidiner
ATE518837T1 (de)	2011-08-15	Indazolamidderivate
DK2142533T3 (da)	2011-12-12	Imidazolidinonderivater
BRPI0814971A2 (pt)	2015-02-03	Proteína
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
EP2187730A4 (en)	2011-05-11	GENETICALLY MODIFIED CHRYSANTHEMENTS
EP2197705A4 (en)	2011-06-01	REAR-VIEW MIRROR
DE602007001593D1 (de)	2009-08-27	Aryl-/alkylvinylsulfon-hyaluronsäurederivate
FIU20100142U0 (fi)	2010-03-24	Järjestely virran muodostamiseksi
HRP20150932T1 (xx)	2015-10-09	Heterocikliäśki spojevi
ATE519760T1 (de)	2011-08-15	Isoxazolimidazolderivate
ATE467626T1 (de)	2010-05-15	Indol-2-yl-piperazin-1-yl-methanon-derivate
ATE527249T1 (de)	2011-10-15	Indole